An interesting article recently published in Science Translational Medicine reports a variable risk of persistent COVID-19 among patients affected by different immunodeficiency conditions. The aforementioned paper’s authors also suggest that suppression of both B and T cell responses is associated with the highest risk of a prolonged SARS-CoV-2 infection [1].
Noteworthy, measles virus (MeV) is a highly lymphotropic pathogen infecting long-lived bone marrow plasmacells. By doing so, MeV may cause a prominent drop in the host’s preexisting antibody response against other infectious agents [2]. This will obviously result in a lower resistance to natural infection as well as in a diminished protection offered by vaccine immunization against the aforementioned pathogens.
Such a peculiar, MeV-induced mechanism of immune amnesia could also putatively affect SARS-CoV-2 evolution, considering also the viral variants which have already shown a high propensity to escape the immunity conferred by natural infection and/or vaccination [3]. Consequently, the global success achieved against COVID-19 thanks to mass vaccine immunization could turn out to be even more adversely affected.
Regretfully, following a significant drop in children’s vaccination campaigns throughout the COVID-19 pandemic, a skyrocketing increase in measles disease cases has been observed in 2023 in Europe (including Italy) and, to a lesser extent, in extra-European Countries compared with 2022 [4]. This reduction in the European pediatric population’s active immunization had already resulted in an 18% increase in estimated disease cases and in a 43% increase in measles fatalities in 2022 compared with 2021, according to a report released last November by the World Health Organization [5]. This should be a top priority in the global fight against an infectious disease causing over 100,000 deaths worldwide, with mass vaccinations against measles between 2000 and 2021 having saved approximately 57 million lives [5].
In conclusion, an extensive measles vaccine coverage of the general pediatric population is urgently needed on a global scale, with international and national Health Authorities putting their best efforts and encouragement forward in this direction.
Conflicts of Interest
The author declares no conflicts of interest.
References
- Li, Y.; Choudhary, M.C.; Regan, J.; Boucau, J.; Nathan, A.; Speidel, T.; Liew, M.Y.; Edelstein, G.E.; Kawano, Y.; Uddin, R.; et al. SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency. Sci. Transl. Med. 2024, 16, eadk1599. [Google Scholar] [CrossRef] [PubMed]
- Mina, M.J.; Kula, T.; Leng, Y.; Li, M.; De Vries, R.D.; Knip, M.; Siljander, H.; Rewers, M.; Choy, D.F.; Wilson, M.S.; et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science 2019, 366, 599–606. [Google Scholar] [CrossRef] [PubMed]
- Di Guardo, G. COVID-19: Measles and Antibiotic Resistance Are a Matter of Concern. Pathogens 2021, 10, 449. [Google Scholar] [CrossRef] [PubMed]
- Minta, A.A.; Ferrari, M.; Antoni, S.; Portnoy, A.; Sbarra, A.; Lambert, B.; Hatcher, C.; Hsu, C.H.; Ho, L.L.; Steulet, C.; et al. Progress toward Measles Elimination—Worldwide, 2000–2022. Wkly. Epidemiol. Rec. 2023, 72, 1262–1268. [Google Scholar] [CrossRef] [PubMed]
- Wong, C. Measles outbreaks cause alarm: What the data say. Nat. News Explain. 2024. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).